share_log

Barrington Research Upgrades Anika Therapeutics to Outperform, Announces $31 Price Target

Barrington Research Upgrades Anika Therapeutics to Outperform, Announces $31 Price Target

巴灵顿研究将Anika Therapeutics上调至跑赢大盘,宣布目标股价为31美元
Benzinga Real-time News ·  2022/11/09 09:26

Barrington Research analyst Michael Petusky upgrades Anika Therapeutics (NASDAQ:ANIK) from Market Perform to Outperform and announces $31 price target.

巴灵顿研究分析师迈克尔·佩图斯基将Anika Therapeutics(纳斯达克股票代码:ANIK)从市场表现上调至跑赢大盘,并宣布了31美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发